Form 4: Prelude Therapeutics CEO, Krishna Vaddi, Awarded Stock Options

Prelude Therapeutics CEO, Krishna Vaddi, was granted stock options to purchase 425,000 shares of common stock on March 1, 2024.

Summary

• On March 1, 2024, Krishna Vaddi, CEO of Prelude Therapeutics Inc., was granted employee stock options.
• These options allow him to purchase 425,000 shares of Prelude Therapeutics' common stock at an exercise price of $4.59 per share.
• The options vest over a four-year period, with 25% vesting on March 1, 2025, and the remaining options vesting monthly thereafter until fully vested, contingent upon continued service to the company.
• The options expire on February 28, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Granting stock options to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of 25% after one year followed by monthly vesting is a common structure to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the CEO's interests with theirs.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates